9,650 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 9,650 shares of the biopharmaceutical company's stock, valued at approximately $290,000.

A number of other institutional investors have also recently bought and sold shares of the business. Arizona State Retirement System boosted its holdings in shares of TG Therapeutics by 0.9% in the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after buying an additional 364 shares during the last quarter. Blue Trust Inc. boosted its stake in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares during the last quarter. Summit Investment Advisors Inc. grew its position in shares of TG Therapeutics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after acquiring an additional 463 shares during the period. Brookstone Capital Management increased its stake in shares of TG Therapeutics by 3.7% during the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock worth $527,000 after purchasing an additional 624 shares during the last quarter. Finally, Daymark Wealth Partners LLC raised its holdings in shares of TG Therapeutics by 1.7% in the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock worth $1,249,000 after purchasing an additional 689 shares during the period. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Performance

TGTX stock traded down $0.22 during midday trading on Friday, reaching $33.64. 2,237,034 shares of the company's stock traded hands, compared to its average volume of 3,022,129. The firm has a market capitalization of $5.34 billion, a PE ratio of -336.37 and a beta of 2.21. The company has a 50-day moving average price of $38.90 and a two-hundred day moving average price of $33.63. TG Therapeutics, Inc. has a 52 week low of $15.16 and a 52 week high of $46.48. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. During the same quarter in the prior year, the business earned ($0.07) EPS. The firm's revenue for the quarter was up 90.4% compared to the same quarter last year. As a group, equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analyst Ratings Changes

TGTX has been the subject of several research reports. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.